Transplant arteriosclerosis is the hallmark of chronic allograft dysfunction (CAD) affecting transplanted organs in the long term 1, 2 . These fibroproliferative lesions lead to neointimal thickening of arteries in all transplanted allografts 2 . Luminal narrowing then leads to graft ischemia and organ demise. To date, there are no known tolerance induction strategies that prevent transplant arteriosclerosis 3, 4 . Therefore, we designed this study to test the hypothesis that human regulatory T cells (T reg cells) expanded ex vivo can prevent transplant arteriosclerosis. Here we show the comparative capacity of T reg cells, sorted via two separate strategies, to prevent transplant arteriosclerosis in a clinically relevant chimeric humanized mouse system. We found that the in vivo development of transplant arteriosclerosis in human arteries was prevented by treatment of ex vivo-expanded human T reg cells. Additionally, we show that T reg cells sorted on the basis of low expression of CD127 provide a more potent therapy to conventional T reg cells. Our results demonstrate that human T reg cells can inhibit transplant arteriosclerosis by impairing effector function and graft infiltration. We anticipate our findings to serve as a foundation for the clinical development of therapeutics targeting transplant arteriosclerosis in both allograft transplantation and other immune-mediated causes of vasculopathy 5 .
Investigating the mechanisms driving the development of transplant arteriosclerosis in situ in transplant recipients is challenging. Whereas protocol biopsies and intravascular imaging provide snapshots of the process and enable the evolution of CAD to be described 6, 7 , the development of a chimeric humanized mouse system has enabled the mechanisms and impact of new interventions to be studied in vivo 8 . Allogeneic peripheral blood mononuclear cells (PBMCs) have been found to elicit immune-mediated rejection of transplanted human arterial segments mimicking the transplant arteriosclerosis seen in human transplantation 8 . Notably, interferon-γ (IFN-γ) elicited the same response in the absence of leukocytes 8 , supporting the concept that both immune and nonimmune mechanisms contribute to the process. Here we investigate the possibility of attenuating the fibroproliferative lesions seen with transplant arteriosclerosis by using ex vivo-expanded human T reg cellular therapy, compare the capacity of CD25 hi CD4 + versus CD127 lo CD25 + CD4 + cells to suppress allogeneic immune responses and evaluate the impact of T reg cells on IFN-γ production.
We FACS-sorted human T reg cells from healthy donor PBMCs into CD25 hi CD4 + cells (designated CD25 hi ) or CD127 lo CD25 + CD4 + cells (designated CD127 lo ) to greater than 94% purity (n = 5 independent experiments; Supplementary Fig. 1a ). After sorting, we expanded the cells in vitro with recombinant human IL-2 and beads coated with CD3-and CD28-specific antibodies ( Fig. 1a) 9, 10 . Both populations consistently expanded more than 600-fold (n = 5 expansions; Supplementary Fig. 1b ). After expansion, both subsets retained expression of T reg cell markers, including CD25, forkhead box P3 (FoxP3), glucocorticoid-induced tumor necrosis factor receptor (GITR) and cytotoxic T lymphocyte antigen-4 (CTLA-4) (Fig. 1b,c and Supplementary Fig. 1c ) 11 . Notably, we observed substantial differences in the expression of CD127, CD62L and CD27 ( Fig. 1c) . Moreover, in vitro suppression assays consistently revealed a higher suppressive capacity in CD127 lo sorted cells toward allostimulated autologous PBMCs (n = 5) as well as toward CD25 − CD4 + effector cells (n = 3) after expansion ( Fig. 1d,e ). Expanded CD127 lo cells expressing CD62L and CD27 suppressed PBMCs much more efficiently than did cells expressing low levels of CD62L, CD27 or both (Fig. 1f) . The molecular mechanism of suppression by expanded T reg cells in vitro was not dependent on interleukin-10 (IL-10) or CTLA-4 ( Supplementary Fig. 2a ) and required cell-to-cell contact ( Supplementary Fig. 2b ). Moreover, both CD25 hi CD4 + and CD127 lo CD4 + expanded T reg cells inhibited dendritic cell maturation, as indicated by the reduction in CD86 expression ( Supplementary  Fig. 2c,d) . The expanded T reg populations could be frozen for storage without loss of functional activity (Supplementary Fig. 3a ) and exerted their suppressive ability even over human leukocyte antigen-mismatched PBMCs (Supplementary Fig. 3b ).
Next, we tested the functional activity of the CD25 hi CD4 + and CD127 lo CD4 + expanded cells from five separate PBMCs donors in vivo. Human internal mammary arterial (IMA) side branches, procured from patients undergoing coronary artery bypass surgery, were transplanted into the infrarenal aorta of BALB/c Rag2 −/− ;Il2rg −/− In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells mice, which are deficient in T, B and NK cells. The next day, we used 1 × 10 7 allogeneic or autologous PBMCs to inoculate mice bearing human arterial grafts. We maximally dilated transplanted human arterial grafts and collected them 30 d after transplantation ( Fig. 2a) . In mice reconstituted with allogeneic PBMCs (defined as >1% splenic human leukocyte chimerism; Supplementary Fig. 4 ) we observed a significant amount of vascular intimal hyperplasia and a decrease in luminal diameter in the transplanted vessels as compared to that of vessels transplanted into mice that either did not receive human PBMCs or were reconstituted with PBMCs autologous to the arterial graft ( Fig. 2b-e and Supplementary Table 1 ). Notably, the neointimal proliferation seen in rejected arterial grafts was allospecific to the human vessel, as the native mouse aorta before the suture line was not affected (Supplementary Fig. 5a ). Moreover, we found that xenoresponses have only a minor role in this system, as evidenced by in vitro mixed lymphocyte reactions (MLRs) in which allohuman responses predominated over any and all xenoresponses ( Supplementary Fig. 5b) . In vitro analysis of precursor frequency, measured by IFN-γ enzymelinked immunospot (ELISPOT) or proliferation, showed a high frequency of donor alloantigen-specific responding cells upon re-stimulation, irrespective of the presence or absence of mouse splenocytes ( Fig. 2f,g) .
We then reconstituted mice transplanted with human vessels with human PBMCs and ex vivo expanded CD25 hi or CD127 lo cells from the same allogeneic blood donor at a 1:1 ratio. Both CD25 hi and CD127 lo populations had a significant impact on the development of transplant arteriosclerosis in vivo without inhibiting the rate of reconstitution ( Fig. 2h-j and Supplementary Fig. 4b-d ). Analysis of vessels transplanted into mice reconstituted with human T reg cells only was not feasible, as the level of reconstitution achieved with fractionated CD4 + T cells alone was <1% (data not shown). The vasculopathy seen in chimeric humanized mice treated with CD25 hi T reg cellular therapy was significantly less than that of mice reconstituted with allo-PBMCs alone (P = 0.0013); however, transplant arteriosclerosis was still evident in these grafts at varying degrees ( Fig. 2h,j) . In contrast, mice treated with CD127 lo , ex vivo-expanded T reg cells showed almost complete abrogation of transplant arteriosclerosis without such variation between different PBMCs and vessel donors, corroborating our in vitro results ( Figs. 1 and 2i,j) . Moreover, in the presence of T reg cell therapy, IFN-γ production by PBMCs was markedly diminished when compared to stimulation of PBMCs with alloantigen in the absence of T reg cells either in vivo (Fig. 3a,b and Supplementary Fig. 6a ) or in vitro ( Fig. 3c and Supplementary Fig. 6b ).
We confirmed the ability of T reg cells to inhibit the secretion of IFN-γ in vivo, which is thought to be integral to the development of transplant arteriosclerosis 8, 12, 13 , by testing serum samples collected from human leukocyte-engrafted mice; upregulation of human IFN-γ by human PBMCs alone was substantially inhibited by CD127 lo T reg cellular therapy ( Fig. 3a) . Of note, the expression of IFN-γ within the graft itself was also significantly inhibited by treatment with CD127 lo T reg cells, as indicated by real-time PCR analysis ( Fig. 3b ; P < 0.01). Suppression of IFN-γ expression within the allograft correlated with increased detection of intragraft FoxP3 mRNA in mice treated with CD127 lo T reg cells ( Fig. 3b) , indicating that CD127 lo T reg cells may infiltrate the graft. Histological assessment revealed that virtually all human graft infiltrating cells were CD3 + T cells (854 ± 280 human CD45 + cells versus 845 ± 318 human CD3 + cells in the neointima in the PBMC group; means ± s.d.). Human CD4 + T cell and CD8 + T cell infiltration of both the graft adventitia and neointima 14 was markedly decreased in mice treated with PBMCs and CD127 lo T reg cell therapy compared to that in mice reconstituted with PBMC alone or with PBMCs and CD25 hi cells ( Fig. 3d) . Taken together, these data suggest that treatment with T reg cells may inhibit the development of transplant arteriosclerosis by preventing the effector response of PBMCs and the mobilization of IFN-γ-producing cells to an allograft 15, 16 .
We then investigated the potency of the effect of CD127 lo T reg cells on the development of transplant arteriosclerosis in the humanized mouse model. When we transferred 2 × 10 6 CD127 lo T reg cells with 1 × 10 7 PBMCs, we also observed a significant decrease in the development of vasculopathy when compared to transplanted mice inoculated with PBMCs alone ( Fig. 4 ; P < 0.05). However, the efficacy of regulation was lost when we transferred 1 × 10 6 CD127 lo T reg cells with 1 × 10 7 PBMCs (Fig. 4d) . The level of transplant arteriosclerosis seen in mice receiving one fifth as many CD127 lo T reg cells was similar to that of mice receiving PBMC + CD25 hi T reg cells at a 1:1 ratio (Fig. 4f) . Additionally, CD4 + and CD8 + lymphocytes produced less IFN-γ in vitro when cultured with CD127 lo T reg cells at a 1:1 and a 5:1 PBMC: T reg cell ratio, confirming the increased potency of CD127 lo T reg cells (Fig. 4g) . Taken together, these data suggest that titrated numbers of ex vivo-expanded T reg cells sorted on the basis of CD127 lo expression are five times more potent than CD25 hi T reg cells.
These data demonstrate the unique ability of ex vivo-expanded human T reg cells to successfully abrogate the development of transplant arteriosclerosis in vivo. Over the past decade, both thymus-derived and antigen-induced T reg cells, initially identified as CD25 + CD4 + , have been highlighted for their suppressive capabilities in vitro and in vivo 11, 17, 18 and their therapeutic potential in the regulation of autoimmunity, allergy and immune-mediated transplant rejection. Although the results presented here are promising, they must also be interpreted with caution, For example, mice treated with T reg cell therapy lost medial architecture in the graft when compared to native arterial sections or mice treated with PBMCs alone (Supplementary Fig. 7) .
Therefore, the translation of these results to the clinic is probably dependent upon the isolation of pure populations of suppressive cells that can reproducibly and safely abrogate disease. Crucial to this process is the identification of markers that permit the isolation and enrichment of viable T reg cells for therapeutic transfer. The recent observation of the inverse correlation between the IL-7 receptor-α (CD127) subunit and the suppressive capacity of CD25 hi CD4 + T reg cells provides an additional potential target to isolate and expand cells with increased suppressive function ex vivo [19] [20] [21] . In mouse models, only the subpopulation of CD25 + CD4 + T reg cells expressing CD62L + was responsible for protection against lethal acute graft-versus-host disease 22 . Therefore, the higher expression of CD62L on the ex vivo-expanded CD127 lo T reg cells used here may be advantageous in clinical situations, allowing for more efficient homing to secondary lymph nodes, as well as in the chimeric humanized in vivo model used here, given the high conservation of the CD62L molecule between species 23 . Additionally, the downregulation of CD127 along with the upregulation of CD27 (Fig. 1) have been correlated previously to a highly suppressive subset of T reg cells believed to exert their effects locally (that is, in allografts or draining lymph node) rather than recirculating systemically 19, 24 . The paradigm that has been proposed to explain the development of transplant arteriosclerosis is one of local effector cell-mediated recruitment of rapidly proliferating vascular smooth muscle cells, leading to neointimal formation and arterial luminal occlusion 3 . With our findings, it seems that immunoregulation of these locally destructive effector cells may be feasible with the use of T reg cellular therapy. However, further tests of the efficacy and safety of these cells are essential.
MeTHODs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
ONLINe MeTHODs
Mice. We obtained BALB/c Rag2 −/− ;Il2rg −/− (H2 d ) mice from Charles River Laboratories and housed them under specific pathogen-free conditions. We performed all experiments using protocols approved by the Committee on Animal Care and Ethical Review at Oxford University and in accordance with the UK Animals (Scientific Procedures) Act 1986. We used mice between the ages of 6 and 10 weeks. The vast majority of mice (over 75%) reconstituted with human PBMCs showed >1% splenic engraftment defined as fully reconstituted. The level of reconstitution was routinely over 10% and did not correlate with amount of arteriosclerosis seen (S.N.N., G.W. & K.J.W., unpublished observations).
Procurement of human arterial side branches. We obtained perforating side branches of the IMA during procurement of the left and right IMA in a skeletonized fashion and immediately placed them in a 4.0% phenoxybenzamine and normal saline solution 25 . Human tissue used for this study was obtained under the ethical reference number 04/Q1605/89. The study was approved by UK National Research Ethics Service, Oxfordshire REC B. Informed consent was obtained from all subjects.
Aortic interposition grafting. Aortic interposition grafts were performed with human IMA side branches into the abdominal aorta of BALB/c Rag2 −/− ;Il2rg −/− mice with an end-to-end anastomosis using a previously described technique 26 .
Sorting and expansion of human CD25 hi T cells and CD127 lo T cells.
We isolated PBMCs from buffy coats provided by the National Blood Service by Ficoll-Paque (GE Healthcare) gradient centrifugation. CD4 + T cells were then enriched with the Human CD4 + Lymphocyte Enrichment Set (BD), stained with appropriate antibodies (to CD4, labeled with allophycocyanin; to CD25, labeled with phycoerythrin; to CD127, labeled with phycoerythrin; to CD25, labeled with allophycocyanin; and to CD4, labeled with PerCP, all BD) and sorted with a BD FacsARIA cell sorter (BD). CD4 + T cells expressing high amounts of CD25 (CD25 hi CD4 + ) and low amounts of CD127 (CD127 lo CD25 + CD4 + ) were subsequently sorted and recovered. In a limited number of experiments, we stained whole PBMCs for sorting, giving a similar purity after each sort (more than 96%). Cells were cultured in RPMI 1640 medium supplemented with l-glutamine, penicillin-streptomycin (all PAA Laboratories), sodium pyruvate (Gibco) and 10% of human AB pooled serum (UK National Blood Service). For expansion, sorted cells were cultured in the presence of recombinant human IL-2 (1,000 U ml −1 ) (Chiron) and Human T-Expander CD3/CD28 Dynabeads (Invitrogen) in a 1:2 cell to bead ratio for two rounds of expansion, 7 d each. After the second round of expansion, beads were removed and cells were silenced for 2 d in medium containing 200 U ml −1 of IL-2 ( Fig. 1a) . After each expansion, the phenotype of cells were assessed by staining for FoxP3 (eBiosciences), GITR (R&D Systems), CD25, CTLA-4, CD127, CD27 and CD62L (BD).
Flow cytometry. For analysis of in vivo experiments on post-operative day 30, we generated single-cell suspensions from spleens and performed a red cell lysis. For phenotypic analysis, antibodies against human CD3 (eBioscience), CD4 (Caltag), CD8, CD25, CD45, and CD127 (BD) were used.
For intracellular cytokine analysis, cells were stimulated with irradiated allogeneic PBMCs for 5 d and re-stimulated for 5 h with phorbol 12-myristate 13-acetate (100 ng ml −1 , Sigma), ionomycin (1 μg ml −1 , Sigma) and monensin (GolgiStop, 1 μl ml −1 , BD) before being stained with antibodies to CD4, CD8, CD3 (BD) and the viability dye 7-AAD (eBiosciences). We then fixed and permeabilized cells and stained them with antibody to intracellular IFN-γ (BD).
In vitro suppression assays. We tested the suppressive activity of expanded CD25 hi or CD127 lo cells by using an in vitro suppression assay. Autologous PBMCs (1 × 10 5 ) were incubated with irradiated allogeneic PBMCs (1 × 10 5 ) and varying numbers of expanded CD25 hi or CD127 lo cells. We then assessed proliferation after 7 d by adding 3 H-thymidine (Perkin Elmer) for the last 16 h of culture.
Adoptive transfer of human cells.
In all experiments, human PBMCs were obtained from random donors and the data pooled. We injected 1 × 10 7 Ficoll-Paque-purified human PBMCs intraperitoneally into recipient mice. Alternatively, human PBMCs were adoptively transferred in the same fashion with an equal number of CD25 hi or CD127 lo ex vivo-expanded human T cells. In the described titration experiments, 2 × 10 6 CD127 lo or 1 × 10 6 CD127 lo cells were co-transferred with 1 × 10 7 PBMCs.
Enzyme-linked immunosorbent assay for human IFN-g. We performed ELISA per the manufacturer's protocol (eBioscience ELISA Ready-SET-Go! Kit).
Cytokine bead array. Cytokine multiplex for T H 1 and T H 2 cytokines were stained with two-color (phycoerythrin and FITC) bead array systems manufactured by Bender Medsystems. The assay was carried out following the manufacturer's protocols. The cytokines detected were IL-6, IL-8, IL-10, IL-2, IFN-γ, IL-12p70, TNF-β, TNF-α, IL-5 and IL-4.
Enzyme-linked immunospot. We performed IFN-γ ELISPOT (BD Biosciences) in three to six repeats with 5 × 10 4 responder cells and 1 × 10 5 irradiated stimulatory cells per well, incubated for 15 h. The assay was carried out following the manufacturer's protocol.
Real-time reverse transcription PCR. Total RNA was isolated from arterial grafts with the NucleoSpin RNA XS kit (Fisher Scientific), followed by cDNA synthesis using the High-Capacity RNA-to-cDNA kit (Applied Biosystems). Real-time quantification was performed with Stratagene Mx3000P (Agilent Technologies) using the HPRT probe and primers as described in ref. 27 and TaqMan Gene Expression Assays (Applied Biosystems) for IFN-γ and FoxP3. Quantification of the gene of interest was analyzed by ΔC t method.
Histology. Thirty days after transplantation, we procured aortic grafts which were then snap-frozen in optimal cutting temperature embedding medium before cryostat sectioning at a thickness of 6−10 μm. After drying, sections were fixed in 100% acetone for 10 min at 4 °C and stored in −80 °C until further use. We then blocked all sections with 10% BSA and 5% mouse serum at 20 °C for 30 min. Primary antibodies, mouse antibody to human CD4 (BD) and mouse antibody to human CD8 (BD) were then applied. After several washes, horseradish peroxidase-conjugated secondary antibody (DAKO Cytomation) was applied, and sections were visualized with diaminobenzidene (Sigma).
Computational and statistical analyses. We analyzed data from mice with >1% human CD45 + live leukocytes in the spleen, as measured by flow cytometry. Morphometric analysis of transplant arteriosclerosis on EvG-stained sections were measured as previously described 18 . Percentage intimal expansion was calculated with the following formula: % intimal expansion = ((A I − A L ) / A I ) × 100; where A I is the area within the internal elastic lamina and A L is the luminal area.
Statistical evaluations were performed with Graphpad Prism software. Statistical significance was determined with the Mann-Whitney U test. P < 0.05 was considered statistically significant. 
